| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary targets of OD36 are RIPK2 and ALK2. It acts as a potent inhibitor of RIPK2 with an IC50 of 5.3 nM. It also binds efficiently to the ALK2 kinase ATP pocket with a Kd of 37 nM. By inhibiting RIPK2, it downregulates MAPK signaling induced by MDP and decreases cellular infiltration induced by MDP in neutrophils and lymphocytes.
|
|---|---|
| ln Vitro |
ALK2 and ALK2 R206H are also inhibited by OD36, with IC50 values of 47 and 22 nM, respectively[1]. With a KD of 90 nM, OD36 has action against ALK1 [2]. Osteogenic differentiation and mutant ALK2 signaling are successfully inhibited by OD36 [2]. In KS483 cells, OD36 (0.1–1 μM; 24 hours) efficiently suppresses BMP-6 (50 ng/mL)-induced p-Smad1/5 [2]. Endothelial colony-forming cells (ECFC) of fibrodysplasia ossificans progressive (FOP) fully inhibit the activation of Smad1/5 and the gene targets ID-1 and ID-3 in response to activin A when preincubated with OD36 (0.5 μM) [2].
In vitro, OD36 inhibits RIPK2 with an IC50 of 5.3 nM. It is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket, with a Kd of 37 nM. It inhibits Tyr and Ser/Thr-directed activities of RIPK2 and downregulates MAPK signaling induced by MDP. Its activity is typically measured using kinase assays with purified enzymes. |
| ln Vivo |
In a mouse model of acute peritonitis, OD36 (6.25 mg/kg; intraperitoneal injection; once) decreases inflammation [3].
In vivo, OD36 decreases cellular infiltration induced by MDP in neutrophils and lymphocytes. This suggests that the compound has anti-inflammatory effects in vivo. Its ability to inhibit RIPK2 and downregulate MAPK signaling contributes to its anti-inflammatory activity. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for OD36 involve kinase activity assays using purified RIPK2 or ALK2 enzymes. The compound's inhibitory activity is measured by monitoring the phosphorylation of a substrate peptide or protein in the presence of ATP. IC50 and Kd values are determined from dose-response curves and binding studies.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: KS483 Cell Tested Concentrations: 0.1, 0.2 and 1 μM Incubation Duration: Experimental Results: Inhibition of BMP-6-induced p-Smad1/5. In vitro cellular assays for OD36 are conducted in cells that express RIPK2 or respond to MDP stimulation. Cells are treated with the compound, and MAPK signaling is assessed by measuring phosphorylation of downstream targets such as ERK, JNK, or p38 using western blotting. Its effects on MDP-induced cytokine production can also be measured. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice, muramyl dipeptide (MDP)-induced peritonitis model [3]
Doses: 6.25 mg/kg Route of Administration: intraperitoneal (ip) injection, 30 minutes before MDP Experimental Results: Inhibited the influx of inflammatory cells into the peritoneum Recruits, particularly neutrophils, and to a lesser extent lymphocytes. Expression of RIPK2-specific genes as well as inflammatory cytokine and chemokine genes was diminished. In vivo animal studies for OD36 are conducted in animal models of inflammation, such as MDP-induced peritonitis. Animals are administered the compound orally or intraperitoneally, and cellular infiltration into the peritoneal cavity is assessed by counting neutrophils and lymphocytes. Its effects on inflammatory cytokine levels are measured. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of OD36 indicate it has a molecular weight of 337.78 and a molecular formula of C16H15ClN4O2. It is a macrocyclic compound. Its bioavailability and other PK parameters would be determined in preclinical studies for its use as a research tool. The compound is typically stored as a powder at appropriate conditions.
|
| Toxicity/Toxicokinetics |
Toxicological information for OD36 is limited to its use as a research chemical. As a kinase inhibitor, it may have effects on cell signaling and inflammation. Comprehensive toxicology studies would be required for its use in vivo, including assessments of its effects on immune function and organ toxicity.
|
| References |
|
| Additional Infomation |
OD36 is a research compound used as a potent and specific inhibitor of RIPK2. It is also a macrocyclic inhibitor that binds to ALK2. It is used to study RIPK2-mediated signaling and inflammation. It is available from research chemical suppliers for preclinical studies. It is not approved for clinical use.
|
| Molecular Formula |
C16H15CLN4O2
|
|---|---|
| Molecular Weight |
330.772
|
| Exact Mass |
366.065
|
| Elemental Analysis |
C, 58.10; H, 4.57; Cl, 10.72; N, 16.94; O, 9.67
|
| CAS # |
1638644-62-8
|
| Related CAS # |
OD36 hydrochloride;2387510-88-3
|
| PubChem CID |
135567262
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
402
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=CC2=CC(=C1)C1C=NN3C=CC(=NC3=1)NCCOCCO2
|
| InChi Key |
KTSDBMVHAKWDRK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15ClN4O2/c17-12-7-11-8-13(9-12)23-6-5-22-4-2-18-15-1-3-21-16(20-15)14(11)10-19-21/h1,3,7-10H,2,4-6H2,(H,18,20)
|
| Chemical Name |
4-chloro-7,10-dioxa-13,17,18,21-tetrazatetracyclo[12.5.2.12,6.017,20]docosa-1(20),2(22),3,5,14(21),15,18-heptaene
|
| Synonyms |
OD 36; OD-36; OD36
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~100.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0232 mL | 15.1162 mL | 30.2325 mL | |
| 5 mM | 0.6046 mL | 3.0232 mL | 6.0465 mL | |
| 10 mM | 0.3023 mL | 1.5116 mL | 3.0232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
